In terms of market performance, Astrazeneca plc ADR had a somewhat inconsistent run in. The highest value for the stock in the past year was $87.68 on 08/30/24, while the lowest value was $61.24 on 04/09/25. 52-week price history of AZN Stock Analyzing the 52-week
Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Astrazeneca plc ADR’s current trading price is -20.33% away from its 52-week high, while its distance from the 52-week low is 14.06%.
The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Astrazeneca plc ADR’s current trading price is -23.95% away from its 52-week high, while its distance from the 52-week low is 8.88%. The stock’s price
Astrazeneca plc ADR’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $87.68 on 08/30/24 and a low of $61.24 for the same time frame on 04/09/25. 52-week price history of AZN Stock Studying a stock’s 52-week price
Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Astrazeneca plc ADR’s current trading price is -20.24% away from its 52-week high, while its distance from the 52-week low is 14.19%.
Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Astrazeneca plc ADR’s current trading price is -22.42% away from its 52-week high, while its distance from the 52-week low is 11.07%.
After the German government recommended its administration to people aged 18 to 64 years of age only, AstraZeneca plc (AZN) defended its vaccine’s effectiveness against the new coronavirus in the elderly. A spokesman for the British-Swedish group AstraZeneca plc (AZN) explained that the newest analysis
Pharma giant AstraZeneca plc (NASDAQ: AZN) pulled out of talks in Brussels in response to delays in the coronavirus vaccine delivery, a development that represents another escalation between the company and the European Union, as reported by Bloomberg. European Union officials have been pressuring the company
Sonos Inc (SONO) soared 29.84 percent after the Californian maker of wireless audio speakers posted performance well above estimates for its fourth fiscal year which ended at the end of September. Compared with the $299 million predicted by the FactSet consensus, revenue jumped 15.5 percent
All rights reserved © 2024, Powered By Smart TechOne